This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Preclinical Animal Pharmacodynamics (PD) Study
Introduction
BioVenic's comprehensive Preclinical Animal Pharmacodynamics (PD) Study services provide high-quality in vivo efficacy validation across diverse disease models. By combining sophisticated animal modeling with advanced bioanalytical suites, we deliver robust solutions that simplify non-GLP workflows and provide clear "Proof of Concept" for your lead candidates.
Our Services
Expert Disease Model Construction
BioVenic has a large library of disease models to check drug effectiveness, focusing on realistic conditions. Our experts make sure each model matches your drug's action.
| Model Category | Induction Method | Research Focus | Common Models |
|---|---|---|---|
| Oncology | Cell line-derived xenograft (CDX), Patient-derived xenograft (PDX) | Tumor Volume Inhibition (TGI), survival rates, and tumor microenvironment. | Subcutaneous/Orthotopic tumors, Metastatic models. |
| Metabolic | High-fat diet (HFD) induction, chemical induction (e.g., STZ) | Glucose homeostasis, lipid metabolism, and weight management. | Type II Diabetes, Obesity, NASH/NAFLD. |
| Inflammation | Chemical irritants, collagen induction, adoptive cell transfer | Cytokine storms, joint swelling, and tissue infiltration. | RA (CIA model), IBD (DSS model), Psoriasis. |
| Neuroscience | Neurotoxin injection, transgenic breeding | Functional recovery, neuroprotection, and synaptic plasticity. | Parkinson's (MPTP/6-OHDA), Alzheimer's (APP/PS1). |
Strategic Sample Collection
Precision in PD starts with the sample. BioVenic provides meticulous biological sample collection services at critical time points following administration to capture the peak pharmacodynamic effect.
Systemic Samples: Whole blood, serum, and plasma for biomarker and cytokine analysis.
Target Tissue Harvesting: Precise removal of organs like liver, kidney, brain (microdissection), or heart.
Specialized Matrices: Collection of cerebrospinal fluid, synovial fluid, urine, and feces.
Tumor Biopsies: Sampling tumor tissue to check drug penetration and target engagement.
Advanced Bioanalytical Analysis
BioVenic's PD platform integrates cutting-edge molecular and cellular biology techniques to translate biological samples into actionable data. We adjust pre-processing and detection methods for your molecule's needs.
Protein & Cytokine Analysis: ELISA, MSD, Western Blotting.
Gene Expression: qPCR and ddPCR for mRNA suppression or gene expression.
Cellular Profiling: Multi-color Flow Cytometry for immune cell analysis.
Histopathology: H&E staining, Immunohistochemistry, and Immunofluorescence for tissue changes.
Biochemical Assessment: Blood chemistry and hematology panels.
Specialized Behavioral Studies
For CNS and pain research, behavioral assessments provide a full view of recovery beyond biochemical markers.
Motor Function: Rotarod Test, Pole Test, and automated gait analysis.
Cognitive & Memory: Morris Water Maze, Y-maze, and Novel Object Recognition.
Psychological Evaluation: Forced Swim Test, Sucrose Preference Test, and Open Field Test.
Social Interaction: Three-chamber social interaction test for neurodevelopmental assessments.
BioVenic Preclinical Animal Pharmacodynamics (PD) Service Workflow
Applications of BioVenic Preclinical Animal Pharmacodynamics (PD) Study
BioVenic's PD services are optimized for a wide array of drug modalities:
Small Molecules: Target occupancy and enzyme inhibition.
Biologics: Monoclonal antibodies, Bispecifics, and ADC effectiveness.
Nucleic Acid Drugs: mRNA knockdown for siRNA and ASO.
Gene Therapies: Check transgene expression and function.
Vaccine Candidates: Immunogenicity and antibody titer assessments.
Advantages of BioVenic Preclinical Pharmacodynamics (PD) Study
Extensive Model & Cell Library
Access a massive repository of validated tumor cell lines and specialized disease models, with the capability for custom model development.
Integrated PK/PD Synergy
Seamlessly combine pharmacokinetics and pharmacodynamics in a single study to establish clear dose-response relationships.
Robust Detection Suite
A comprehensive "one-stop" bioanalytical platform capable of handling diverse and complex sample matrices.
What You Get: Preclinical Animal PD Study Deliverables
To ensure your drug development program is milestone-driven and decision-ready, BioVenic provides a comprehensive suite of deliverables across the pharmacodynamics (PD) evaluation spectrum-from sophisticated model construction to high-dimensional bioanalytical data.
Stage 1: Expert Disease Model Validation
Outputs:
- Validated Disease Model Profile: Confirmation of model induction (e.g., CDX/PDX for Oncology, HFD/STZ for Metabolic, or Transgenic for Neuroscience).
- Baseline Assessment Report: Initial physiological and biochemical parameters (e.g., tumor volume, glucose levels, or motor function) ensuring the model matches your drug's mechanism of action.
- Study Design Blueprint: A customized PD study plan including dosing cohorts, frequency, and specific research focus (e.g., TGI, cytokine storms, or neuroprotection).
Stage 2: Strategic Sample Collection & Processing
Deliverables:
- Systemic Bio-matrix Package: Collection and stabilization of whole blood, serum, and plasma at critical time points to capture peak effects.
- Target Tissue & Specialized Matrix Inventory: High-precision harvesting of organs (liver, kidney, brain microdissection) and specialized fluids (CSF, synovial fluid, urine/feces).
- Tumor Biopsy Report: Documentation of sampled tumor tissue for downstream analysis of drug penetration and target engagement.
Stage 3: Advanced Bioanalytical Data Package
Outputs:
- Protein & Molecular Profiles: Comprehensive data from ELISA, MSD, Western Blotting, and gene expression analysis (qPCR/ddPCR).
- Cellular & Histopathology Gallery: Multi-color Flow Cytometry results for immune profiling alongside high-resolution H&E, IHC, and IF staining images.
- Biochemical Assessment: Full hematology and blood chemistry panels to quantify systemic physiological shifts.
Stage 4: Behavioral & Functional Recovery Report
Deliverables:
- Quantitative Motor & Cognitive Metrics: Raw data and analysis from specialized tests (e.g., Rotarod, Morris Water Maze, Y-maze).
- Psychosocial & Pain Evaluation: Insights into psychological recovery and social interaction (e.g., Forced Swim Test, Three-chamber test).
- Integrated PD Summary: A final report correlating behavioral recovery with biochemical markers to provide a holistic view of drug effectiveness.
Case Study: PD Evaluation & Target Engagement in Renal Models
BioVenic provides a high-precision pharmacodynamics evaluation service optimized for assessing therapeutic efficacy in hereditary solid tumor models, such as the Tsc2+/- knockout system. Our analytical suite focuses on the high-sensitivity quantification of downstream effectors via integrated IHC and Western Blotting. To characterize the cellular response, we provide precise monitoring of turnover markers, including Ki-67 for proliferation and cleaved caspase-3 for apoptosis. Our robust PD framework is specifically designed to provide the critical data required to define the optimal biological dose and accelerate the clinical transition of candidates for refractory renal cell carcinomas.
Fig. 1 Efficacy of GSK2126458 and rapamycin on renal tumours in Tsc2+/- mice1
FAQs
Can you perform custom disease model development if my target is unique?
Yes. We specialize in developing tailored models via specific induction protocols or specialized cell line engineering to match your drug's unique mechanism.
What is the typical turnaround time for a standard tumor efficacy study?
Timelines depend on model growth, but usually, the in vivo phase and reporting finish in 4 to 8 weeks.
Are your services compliant with international animal welfare standards?
Yes, all studies follow strict ethical guidelines for animal welfare and data integrity.
Contact Us
Ready to validate your candidate's efficacy with precision? BioVenic senior scientific team is here to help you navigate the complexities of preclinical PD studies. From custom model construction to sophisticated behavioral and molecular analysis, we provide the robust data needed to move your project forward with confidence. Contact us today for a technical consultation or a customized quote, and let's accelerate your journey from the lab to the clinic together.
Reference
- Narov, Kalin et al. "The dual PI3K/mTOR inhibitor GSK2126458 is effective for treating solid renal tumours in Tsc2+/- mice through suppression of cell proliferation and induction of apoptosis." Oncotarget vol. 8,35 58504-58512. 19 Apr. 2017. https://doi.org/10.18632/oncotarget.17215. Distributed under Open Access license CC BY 3.0. Without modification.